<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01165840</url>
  </required_header>
  <id_info>
    <org_study_id>AMAIRB97</org_study_id>
    <secondary_id>5UL1RR024982-02</secondary_id>
    <nct_id>NCT01165840</nct_id>
  </id_info>
  <brief_title>Effect of Weight and/or Obesity on Dapsone Drug Concentrations</brief_title>
  <official_title>Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Texas Tech University Health Sciences Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will find how weight affects the dosing of a drug called dapsone. Currently, the
      amount of dapsone a patient receives is the same regardless of the patient's weight.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Clearance</measure>
    <time_frame>72 hours</time_frame>
    <description>Serum clearance of dapsone</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Obesity</condition>
  <condition>Leprosy</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Dapsone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapsone 100 mg PO x 1 dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapsone</intervention_name>
    <description>100 mg PO x 1 dose</description>
    <arm_group_label>Dapsone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects, age &gt;18 years, of all racial and ethnic origins.

          -  Non-English speaking Spanish speakers will be included in the study.

          -  We are recruiting 12 normal or underweight (BMI &lt;25 kg/m2), 12 overweight or obese
             (BMI 25-40 kg/m2), and 12 extremely obese (BMI &gt; 40 kg/m2) for this study. This index
             is calculated using the volunteer's height and weight (Formula: weight (lb) / [height
             (in)]2 x 703). Half of each group will be male; the other half will be female.

        Exclusion Criteria:

          -  Pregnant or nursing or unwilling to use a reliable contraception method during the
             study. The effects of dapsone on pregnancy are unknown. In addition, the metabolic
             changes that accompany pregnancy may alter the concentration-time profile of dapsone,
             so that the pregnancy and post-partum state would be a confounding variable.

          -  Abnormal liver function tests: transaminases&gt;10 times upper limit of normal, Alkaline
             phosphatase&gt;5 times upper limit of normal, total bilirubin&gt;5 times upper limit of
             normal.

          -  History of allergies to dapsone, sulfones, or sulfonamides.

          -  Dapsone, sulfones, or sulfonamides are contraindicated for any reason.

          -  Volunteers unwilling to comply with study procedures.

          -  Current suspected or documented infection of any kind.

          -  Volunteers with colon resection, gastric bypass, lap band, or any other conditions
             inhibiting gastric absorption of drug.

          -  Current or previous participation within 28 days of enrollment in another research
             study that involves the use of medication, contrast, or any other compound that may
             alter blood count and/or blood chemistry (liver function, kidney function or
             electrolyte balance), unless waved by PI.

          -  Donation of 450 milliliters (ml) (one unit) of blood or more within 8 weeks (56 days)
             prior to study enrollment, unless waved by PI.

          -  Current use of zidovudine, amprenavir, rifabutin, rifapentine, or saquinavir.

          -  Creatinine clearance &lt; 70 ml/minute (min) as estimated by the Cockcroft-gault
             equation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Hall, PharmD, MSCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech UHSC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2010</study_first_submitted>
  <study_first_submitted_qc>July 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2010</study_first_posted>
  <results_first_submitted>October 28, 2015</results_first_submitted>
  <results_first_submitted_qc>June 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2016</results_first_posted>
  <disposition_first_submitted>February 4, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 6, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 22, 2014</disposition_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Tech University Health Sciences Center</investigator_affiliation>
    <investigator_full_name>Ron Hall</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Dapsone</keyword>
  <keyword>Leprosy</keyword>
  <keyword>Tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Leprosy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapsone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited into three BMI groups to ensure a wide total body weight distribution, but only one pharmacokinetic model was analyzed with total body weight being one of the potential covariates that was assessed.</recruitment_details>
      <pre_assignment_details>Thirty-seven patient provided consent, but only 36 started the study. One patient provided informed consent but was found to have G6PD and was not allowed to continue.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dapsone</title>
          <description>Dapsone 100 mg PO x 1 dose
Dapsone: 100 mg PO x 1 dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dapsone</title>
          <description>Dapsone 100 mg PO x 1 dose
Dapsone: 100 mg PO x 1 dose</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.2" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Clearance</title>
        <description>Serum clearance of dapsone</description>
        <time_frame>72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapsone</title>
            <description>Dapsone 100 mg PO x 1 dose
Dapsone: 100 mg PO x 1 dose</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Clearance</title>
          <description>Serum clearance of dapsone</description>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>72 hours</time_frame>
      <desc>Participants were in the Clinical Research Unit under nursing supervision 0-24 hours after the dapsone dose. Research clinic visits occured at 48 and 72 hours after the dapsone dose under supervision of a research coordinator.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dapsone</title>
          <description>Dapsone 100 mg PO x 1 dose
Dapsone: 100 mg PO x 1 dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald Hall</name_or_title>
      <organization>Texas Tech University HSC</organization>
      <phone>214-358-9009</phone>
      <email>ronald.hall@ttuhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

